Reports Q4 revenue $515.2M, consensus $518.13M. “I’m exceptionally proud of the progress we made with INGREZZA last year, helping more patients than ever before treat their tardive dyskinesia. In addition, the positive Phase 3 crinecerfont results for the treatment of congenital adrenal hyperplasia opens the door for us to help patients living with a disabling neuroendocrine disorder,” said Kevin Gorman, Ph.D., CEO of Neurocrine Biosciences. “With a strong foundation in INGREZZA, a potential second important growth driver in crinecerfont, and an advancing pipeline, Neurocrine Biosciences is making significant progress towards becoming a leading neuroscience focused company.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- NBIX Earnings this Week: How Will it Perform?
- Neurocrine price target raised to $150 from $145 at Barclays
- Neurocrine director Lyons, Chief Medical Officer Roberts sell $1.3M in stock
- Neurocrine price target raised to $145 from $125 at Barclays
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue